TGF-B1 REGULATES GALECTIN-1 EXPRESSION IN METASTATIC MAMMARY ADENOCARCINOMA CELLS: IMPLICATIONS FOR TUMOR-IMMUNE ESCAPE

CECILIA DAROQUI; JUAN M. ILARREGUI; NATALIA RUBINSTEIN; MARIANA SALATINO; MARTA A. TOSCANO; PAULA VAZQUEZ; LIDIA PURICELLI; ELISA BAL DE KIER-JOFFE; GABRIEL A. RABINOVICH

CANCER IMMUNOLOGY IMMUNOTHERAPY

Springer-Verlag

Año: 2007 vol. 56 p. 491 - 499

0340-7004

Tumors escape from immune surveillance by producing immunosuppressive cytokines and proapototic factors, including TGF-beta and galectin-1 (Gal-1). Since immunosuppressive mechanisms might act in concert to confer tumor-immune privilege, we investigated the potential cross talk between TGF-beta and Gal-1 in highly metastatic mammary adenocarcinoma (LM3) cells. While Gal-1 treatment was not capable of regulating TGF-beta synthesis, a pronounced and dose-dependent increase in Gal-1 expression was observed when tumor cells were treated with TGF-beta(1. )This effect was also observed in the murine lung adenocarcinoma LP07 and in the human breast adenocarcinoma MCF-7 cell lines. TGF-beta1-mediated upregulation of Gal-1 expression was specifically mediated by TbetaRI and TbetaRII, since it was abrogated when LM3 cells were infected with retroviral vectors expressing the dominant negative forms of these receptors. In addition, gal-1 gene sequence analysis revealed the presence of three putative binding sites for Smad4 and Smad3 transcription factors, consistent with the ability of TGF-beta(1) to trigger a Smad-dependent signaling pathway in these cells. Thus, TGF-beta(1) may trigger a Smad-dependent pathway to control Gal-1 expression, suggesting that distinct mechanisms might cooperate in tilting the balance toward an immunosuppressive environment at the tumor site.